RECEIVED CENTRAL FAX CENTER

MAY 2 5 2004

PTO/SB/81 (09-03) Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 10/717,290 Application Number 11/19/2003 **Filing Date POWER OF ATTORNEY** First Named Inventor Yat Sun Or CORRESPONDENCE ADDRESS 6-11 Bicyclic Ketolide Derivatives Title INDICATION FORM 1614 Art Unit TBD **Examiner Name** ENP-038CIP.2 Attorney Docket No. I hereby revoke all previous powers of attorney given in the above-identified patent application and hereby appoint: Practitioners associated with the Customer Number 000038473 X Practitioner(s) named below: Registration Registration Name Name as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith. Please recognize or change the correspondence address for the above-identified application to: x The address associated with the above-mentioned Customer Number: OR The address associated with Customer Number: OR Firm or Individual Name Address City Zip State Country Telephone Fax I am the: Applicant/Inventor. X Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96) SIGNATURE of Applicant or Assignee of Record Proprogreuticals, Inc. by Paul J. Mellett, Senior Vice President and CFO Name Signature Date Telephone 617-607-0800 NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below. Х "Total of forms are submitted otal of I hereby certify that this correspondence is being tacsimile transmitted to: Commissioner for Patente, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below. Karkerne Ptayle

PTO/SE/96 (08-03)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Peperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it displays a valid QMB control number.

STATEMENT UNDER 37 CFR 3.73(b)
Applicant/Patent Owner: ENANTA PHARMACEUTICALS, INC.
Application No./Patent No.: 10/717,290 Filed/Issue Date: November 19, 2003
Entitled: 6-11 Bicyclic Ketolide Derivatives
ENANTA PHARMACEUTICALS, INC. , a CORPORATION (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is: 1. the assignee of the entire right, title, and interest; or
2. an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is% in the patent application/patent identified above by virtue of either:
A. [r] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel <u>TBD</u> , Frame <u>TBD</u> , or for which a copy thereof is attached.
OR .
B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:
From: The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
2. From:To:
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
From: To: The document was recorded in the United States Patent and Trademark Office at
The document was recorded in the United States Patent and Trademark Office at Reel Frame, or for which a copy thereof is attached.
[] Additional documents in the chain of title are listed on a supplemental sheet.
[] Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.
Date Typed or prifted name
617-607-0800 Bull Sullegar
Telephone number Signature
Senior Vice President and CFO Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Comfidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DQ NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.